These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 29955479)

  • 21. Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.
    Rosa F; Schreiner A; Thomas P; Sherif T
    Clin Drug Investig; 2012 Apr; 32(4):267-79. PubMed ID: 22339430
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of Prescribing Patterns of Long-Acting Injectable Antipsychotics Within a Community Health System.
    Netley J; Gaul J; Ferguson C
    J Clin Psychopharmacol; 2019; 39(5):494-498. PubMed ID: 31425464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rehospitalization Rates Among Patients with Psychotic Disorders During Covid-19 Pandemic: Oral Versus Long-Acting Injectable Antipsychotics.
    Mastelić T; Borovina Marasović T; Rakušić M; Martinović D; Lasić D; Uglešić B; Glavina T
    Clin Neuropsychiatry; 2022 Dec; 19(6):365-369. PubMed ID: 36627948
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of Medicaid spending in schizoaffective patients treated with once monthly paliperidone palmitate or oral atypical antipsychotics.
    Xiao Y; Muser E; Fu DJ; Lafeuille MH; Pilon D; Emond B; Wu A; Duh MS; Lefebvre P
    Curr Med Res Opin; 2016; 32(4):759-69. PubMed ID: 26750639
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination of Long-Acting Injectable Antipsychotics in the Treatment of Psychiatric Disorders-A Systematic Review of the Literature and Case Series.
    Youykheang M; Al Hallaq Z; Menelas K; Biskin RS; Dagenais-Beaulé V
    J Clin Psychopharmacol; 2023 Jan-Feb 01; 43(1):20-27. PubMed ID: 36409761
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Healthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics vs oral.
    Offord S; Wong B; Mirski D; Baker RA; Lin J
    J Med Econ; 2013; 16(2):231-9. PubMed ID: 23163287
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment Patterns, Healthcare Resource Utilization and Costs Among Schizophrenia Patients Treated with Long-Acting Injectable Versus Oral Antipsychotics.
    Shah A; Xie L; Kariburyo F; Zhang Q; Gore M
    Adv Ther; 2018 Nov; 35(11):1994-2014. PubMed ID: 30269292
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-Acting Injectable Atypical Antipsychotic Use in Adolescents: An Observational Study.
    Fortea A; Ilzarbe D; Espinosa L; Solerdelcoll M; de Castro C; Oriolo G; Sugranyes G; Baeza I
    J Child Adolesc Psychopharmacol; 2018 May; 28(4):252-257. PubMed ID: 29381388
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antipsychotic Adherence, Resource Use, and Costs Before and After the Initiation of Once-monthly Paliperidone Palmitate Therapy Among Medicaid Beneficiaries With Prior Schizophrenia Relapse.
    Zhdanava M; Lin D; Lafeuille MH; Ghelerter I; Morrison L; Lefebvre P; Joshi K
    Clin Ther; 2021 Mar; 43(3):535-548. PubMed ID: 33589216
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hospitalization resource utilization and costs among Medicaid insured patients with schizophrenia with different treatment durations of long-acting injectable antipsychotic therapy.
    Bera R; Offord S; Zubek D; Lau G; Lin J; Karson C
    J Clin Psychopharmacol; 2014 Feb; 34(1):30-5. PubMed ID: 24135840
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia.
    Schreiner A; Aadamsoo K; Altamura AC; Franco M; Gorwood P; Neznanov NG; Schronen J; Ucok A; Zink M; Janik A; Cherubin P; Lahaye M; Hargarter L
    Schizophr Res; 2015 Dec; 169(1-3):393-399. PubMed ID: 26431793
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preliminary efficacy and tolerability profiles of first versus second-generation Long-Acting Injectable Antipsychotics in schizophrenia: A systematic review and meta-analysis.
    Saucedo Uribe E; Carranza Navarro F; Guerrero Medrano AF; García Cervantes KI; Álvarez Villalobos NA; Acuña Rocha VD; Méndez Hernández M; Millán Alanís JM; Hinojosa Cavada CM; Zúñiga Hernández JA; Fernández Zambrano SM
    J Psychiatr Res; 2020 Oct; 129():222-233. PubMed ID: 32805530
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies.
    Kishimoto T; Nitta M; Borenstein M; Kane JM; Correll CU
    J Clin Psychiatry; 2013 Oct; 74(10):957-65. PubMed ID: 24229745
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term remission in schizophrenia and schizoaffective disorder: results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE).
    Smeraldi E; Cavallaro R; Folnegović-Šmalc V; Bidzan L; Emin Ceylan M; Schreiner A
    Ther Adv Psychopharmacol; 2013 Aug; 3(4):191-9. PubMed ID: 24167692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study.
    Buckley PF; Schooler NR; Goff DC; Hsiao J; Kopelowicz A; Lauriello J; Manschreck T; Mendelowitz AJ; Miller del D; Severe JB; Wilson DR; Ames D; Bustillo J; Mintz J; Kane JM;
    Schizophr Bull; 2015 Mar; 41(2):449-59. PubMed ID: 24870446
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Readmission Rates of Patients with Schizophrenia Treated with Depot Antipsychotics versus Oral Antipsychotics in a Community Hospital.
    Espiridion ED; Lewandrowski C; Shahriari S; Bestoyong DF
    Cureus; 2018 Dec; 10(12):e3775. PubMed ID: 30820394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of Long-Acting Injectable Antipsychotics in Adolescents.
    Pope S; Zaraa SG
    J Child Adolesc Psychopharmacol; 2016 May; 26(4):391-4. PubMed ID: 27028966
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
    Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
    J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Medication-related issues associated with the documentation and administration of long-acting injectable antipsychotics.
    Borja VA; Galbraith K
    Int J Clin Pharm; 2019 Jun; 41(3):623-629. PubMed ID: 30945046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.